Seeking Alpha

Optimer Pharmaceuticals (OPTR) is up 6.4% after Jefferies reiterates a Buy and $17 PT. The firm...

Optimer Pharmaceuticals (OPTR) is up 6.4% after Jefferies reiterates a Buy and $17 PT. The firm is bullish on better-than-expected sales of Optimer's Dificid drug, and on the pending EU launch of the drug by partner Astellas (ALPMY.PK). Jefferies also thinks milestone payment from Astellas will strengthen Optimer's cash position.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)